Shaperon said on the 7th that it will attend the 44th JP Morgan Healthcare Conference (JPM 2026), a pharma-biotech investment event to be held in San Francisco on the 12th to 15th (local time), and give a corporations presentation for partnering with global drugmakers.
The company will also take part in Global IR @JPM 2026, a global IR program co-hosted by the Korea Biotechnology Industry Organization, U.S. law firm Sidley Austin (Sidley Austin LLP), and U.S. biopharma trade media BioCentury (BioCentury).
Shaperon plans to deliver an oral presentation to global investors on development progress and commercialization strategy, focusing on the atopic dermatitis treatment candidate "NuGel" and the diabetic foot ulcer treatment candidate "NuDifin."
Global big pharma companies such as Johnson & Johnson (Johnson & Johnson) and Pfizer (Pfizer) are scheduled to attend the event as investor panelists to review potential collaboration with corporations that have promising pipelines.
NuGel is in phase 2b clinical trials in the United States and Korea. NuGel's strength is a differentiated mechanism that simultaneously regulates from the early stage of inflammation through the amplification stage. The company said demand is steadily increasing for a topical atopic dermatitis treatment that can be used long term, centered on mild to moderate patients.
NuDifin is a treatment candidate that has completed phase 1 and is being developed for the indication, with a mechanism that suppresses inflammatory responses while simultaneously improving the tissue-regeneration environment needed for wound healing. Diabetic foot ulcers are an intractable disease that is difficult to heal due to peripheral neuropathy and impaired blood flow, and effective drug treatments are currently limited.
A Shaperon official said, "We are approaching the end of the U.S. phase 2b trial of NuGel in the first half of this year, and the related technology is protected by patents," adding, "We will use this event to expand exchanges with global drugmakers and financial institutions and make concrete progress on global partnership talks."